

Figure S1 Subgroup analysis of PFS in all patients. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; rwPFS, real-world progression-free survival.

Table S1 Subgroup analysis of PFS by accelerated failure time (AFT) model

Variability	Event/total	Factor ^a (95% CI)	P
Sex			
Male	20/36	Reference	
Female	6/7	0.51 (0.29–0.88)	0.02
Age, years			
<75	20/33	Reference	
≥75	6/10	0.89 (0.57–1.37)	0.59
Smoking history			
Never	16/24	Reference	
Current/Former	10/19	1.04 (0.68–1.6)	0.86
ECOG PS status			
0	4/8	Reference	
1/2	21/34	0.78 (0.4–1.51)	0.46
Tumor stage			
II/III	6/11	Reference	
IV	20/32	0.64 (0.36–1.14)	0.13
Complication			
No	6/11	Reference	
Yes	20/32	0.9 (0.52–1.55)	0.71
Thoracic radiotherapy			
No	18/31	Reference	
Yes	8/12	1.41 (0.93–2.12)	>0.99
Brain radiotherapy			
No	21/38	Reference	
Yes	5/5	0.25 (0.13–0.47)	<0.001
Bone metastasis			
No	19/32	Reference	
Yes	7/11	0.68 (0.44–1.05)	0.08
Brain metastasis			
No	22/38	Reference	
Yes	4/5	1.34 (0.69–2.59)	0.38
Liver metastasis			
No	17/31	Reference	
Yes	9/12	0.62 (0.38–1.01)	0.053

^a, Factor value >1 correlated with decreased risk, and value <1 correlated with increased risk. PFS, progression-free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; CI, confidence interval.




Figure S2 Subgroup analysis of OS in all patients. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; rwPFS, real-world progression-free survival.

Table S2 Subgroup analysis of OS by AFT model

Variability	Event/total	Factor (95% CI)	P
Sex			
Male	8/36	Reference	
Female	4/7	0.69 (0.46–1.04)	0.08
Age, years			
<75	7/33	Reference	
≥75	5/10	0.34 (0.15–0.75)	0.008
Smoking history			
Never	10/24	Reference	
Current/former	2/19	1.78 (1.14–2.79)	0.01
ECOG PS status			
0	2/8	Reference	
1/2	9/34	0.43 (0.25–0.73)	0.002
Tumor stage			
II/III	3/11	Reference	
IV	9/32	1.23 (0.72–2.1)	0.46
Complication			
No	4/11	Reference	
Yes	8/32	0.78 (0.51–1.19)	0.24
Thoracic radiotherapy			
No	8/31	Reference	
Yes	4/12	0.41 (0.17–0.96)	0.04
Brain radiotherapy			
No	10/38	Reference	
Yes	2/5	1.05 (0.62–1.79)	0.84
Bone metastasis			
No	11/32	Reference	
Yes	1/11	3 (0.95–9.49)	0.06
Brain metastasis			
No	9/38	Reference	
Yes	3/5	0.33 (0.13–0.86)	0.02
Liver metastasis			
No	10/31	Reference	
Yes	2/12	1.24 (0.76–2)	0.39

OS, overall survival; AFT, accelerated failure time; ECOG PS, Eastern Cooperative Oncology Group performance status; CI, confidence interval.

Table S3 Change of NLR value before pre- and post-treatment

Patient group	NLR value, mean \pm SD		NLR value, median (range)	
	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
All patients	3.42 \pm 1.57	4.88 \pm 3.66	3.09 (1.38–7.27)	4.19 (0.86–20)
ORR	3.38 \pm 1.55	4.67 \pm 2.98	3.04 (1.38–7.27)	4.19 (0.86–12.69)
Non-ORR	3.54 \pm 1.69	5.41 \pm 5.16	3.77 (1.64–7.25)	4.46 (1.8–20)

NLR, neutrophil-to-lymphocyte ratio; SD, standard deviation; ORR, objective response rate.

Table S4 Change of NLR level pre- and post-treatment in all patients

Pre-treatment	Post-treatment		P
	Low NLR level	High NLR level	
Low NLR level	10	10	0.18
High NLR level	4	15	

NLR, neutrophil-to-lymphocyte ratio.